Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. LICENSE AGREEMENTLicense Agreement • April 8th, 2010 • Furiex Pharmaceuticals, Inc. • Pharmaceutical preparations • California
Portions of this exhibit marked [*] are requested to be treated confidentially. EXCLUSIVE LICENSE AGREEMENT between MAGEN BIOSCIENCES, INC. and ELI LILLY AND COMPANY NOVEMBER 28, 2007Exclusive License Agreement • April 8th, 2010 • Furiex Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) is made and entered into effective as of November 28, 2007 (the “Effective Date”), by and between MAGEN BIOSCIENCES, INC. (“Magen”), a corporation organized and existing under the laws of the State of Delaware, having its principal place of business at 790 Memorial Drive, Suite 101, Cambridge, MA 02139, and ELI LILLY AND COMPANY (“Lilly”), a corporation organized and existing under the laws of the State of Indiana, having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285. Magen and Lilly may be referred to herein individually as a “Party” and collectively as “Parties.”
Portions of this exhibit marked [*] are requested to be treated confidentially. COLLABORATION AND LICENSE OPTION AGREEMENTCollaboration and License Option Agreement • April 8th, 2010 • Furiex Pharmaceuticals, Inc. • Pharmaceutical preparations • Indiana
This Collaboration and License Option Agreement (“Agreement”) is effective as of February 10, 2009 (“Effective Date”). The parties to this Agreement are Eli Lilly and Company having its principal offices at Lilly Corporate Center, Indianapolis, IN 46285 (“Lilly”), and Magen BioSciences, Inc., having its principal offices at 100 Beaver St., Suite 101, Waltham, MA 02453 (“Magen”). Lilly and Magen may be referred to herein individually as a “Party”, and collectively as the “Parties”.
